{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T01:42:18Z","timestamp":1791078138036,"version":"4.1.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2012,12,1]],"date-time":"2012-12-01T00:00:00Z","timestamp":1354320000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Transplantation Proceedings"],"published-print":{"date-parts":[[2012,12]]},"DOI":"10.1016\/j.transproceed.2012.06.072","type":"journal-article","created":{"date-parts":[[2012,11,26]],"date-time":"2012-11-26T19:18:17Z","timestamp":1353957497000},"page":"2966-2970","source":"Crossref","is-referenced-by-count":12,"title":["Conversion to Everolimus in Kidney Transplant Recipients: To Believe or Not Believe?"],"prefix":"10.1016","volume":"44","author":[{"given":"P.","family":"Cotovio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Neves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Mac\u00e1rio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Alves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Mota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.transproceed.2012.06.072_bib1","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/j.transproceed.2011.01.097","article-title":"Conversion to proliferation signal inhibitors-based immuno-suppressive regimen in kidney transplantation: to whom and when?","volume":"43","author":"Sahin","year":"2011","journal-title":"Transplant Proc"},{"key":"10.1016\/j.transproceed.2012.06.072_bib2","first-page":"27","article-title":"Clinical evidence on the use of anti-mTOR drugs in renal transplantation","volume":"31","author":"Hern\u00e1ndez","year":"2011","journal-title":"Nefrologia"},{"key":"10.1016\/j.transproceed.2012.06.072_bib3","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1111\/j.1600-6143.2004.00332.x","article-title":"Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era","volume":"4","author":"Meier-Kriesche","year":"2004","journal-title":"Am J Transplant"},{"key":"10.1016\/j.transproceed.2012.06.072_bib4","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1097\/00007890-199707150-00008","article-title":"SDZ RAD, a new rapamycin derivative: pharmacological properties in vitro and in vivo","volume":"64","author":"Schuler","year":"1997","journal-title":"Transplantation"},{"key":"10.1016\/j.transproceed.2012.06.072_bib5","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1161\/01.CIR.0000033973.06059.04","article-title":"Oral everolimus inhibits in-stent neointimal growth","volume":"106","author":"Farb","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.transproceed.2012.06.072_bib6","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.carrev.2006.05.001","article-title":"Optimal dosing and duration of oral everolimus to inhibit in-stent neointimal growth in rabbit iliac arteries","volume":"7","author":"Waksman","year":"2006","journal-title":"Cardiovasc Revasc Med"},{"key":"10.1016\/j.transproceed.2012.06.072_bib7","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1097\/01.tp.0000252779.56951.bf","article-title":"Effects of everolimus on cellular and humoral immune processes leading to chronic allograft nephropathy in a rat model with sensitized recipients","volume":"83","author":"Koch","year":"2007","journal-title":"Transplantation"},{"key":"10.1016\/j.transproceed.2012.06.072_bib8","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1111\/j.1399-0012.2008.00795.x","article-title":"Early, abrupt conversion of de novo renal transplant patients from cyclosporine to everolimus: results of a pilot study","volume":"22","author":"Holdaas","year":"2008","journal-title":"Clin Transplant"},{"key":"10.1016\/j.transproceed.2012.06.072_bib9","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1097\/TP.0b013e3181af1df6","article-title":"Minimization of maintenance immunosuppression early after renal transplantation: an interim analysis","volume":"88","author":"Bemelman","year":"2009","journal-title":"Transplantation"},{"key":"10.1016\/j.transproceed.2012.06.072_bib10","first-page":"133","article-title":"mTOR inhibitor\/proliferation signal inhibitors: entering or leaving the field?","volume":"23","author":"Rostaing","year":"2010","journal-title":"J Nephrol"},{"key":"10.1016\/j.transproceed.2012.06.072_bib11","doi-asserted-by":"crossref","first-page":"3755","DOI":"10.1681\/ASN.2005060635","article-title":"Rapamycin for treatment of chronic allograft nephropathy in renal transplant patients","volume":"16","author":"Stallone","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.transproceed.2012.06.072_bib12","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/S0140-6736(00)02480-6","article-title":"Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomized multicenter study","volume":"356","author":"Kahan","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.transproceed.2012.06.072_bib13","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1097\/01.tp.0000203894.53714.27","article-title":"A randomized long-term trial of tacrolimus\/sirolimus versus tacrolimus\/mycophenolate versus cyclosporine\/sirolimus in renal transplantation: three year analysis","volume":"81","author":"Ciancio","year":"2006","journal-title":"Transplantation"},{"key":"10.1016\/j.transproceed.2012.06.072_bib14","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1097\/01.TP.0000061606.64917.BE","article-title":"A prospective, randomized clinical trial of cyclosporine reduction in stable patients greater than 12 months after renal transplantation","volume":"75","author":"Pascual","year":"2003","journal-title":"Transplantation"},{"key":"10.1016\/j.transproceed.2012.06.072_bib15","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1111\/j.1600-6143.2006.01398.x","article-title":"Mycophenolate mofetil and sirolimus combination in renal transplantation","volume":"6","author":"Grinyo","year":"2006","journal-title":"Am J Transplant"},{"key":"10.1016\/j.transproceed.2012.06.072_bib16","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1016\/j.transproceed.2007.07.071","article-title":"Use of the new proliferation signal inhibitor everolimus in renal transplant patients in Spain: preliminary results of the EVERODATA registry","volume":"39","author":"Ruiz","year":"2007","journal-title":"Transplant Proc"},{"key":"10.1016\/j.transproceed.2012.06.072_bib17","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1016\/j.transproceed.2009.06.162","article-title":"Complete switch to everolimus in long-term kidney transplants: evolution of the renal function","volume":"41","author":"Fern\u00e1ndez","year":"2009","journal-title":"Transplant Proc"},{"key":"10.1016\/j.transproceed.2012.06.072_bib18","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1016\/j.transproceed.2009.05.013","article-title":"Conversion to everolimus in kidney transplant recipients with decreased renal function","volume":"41","author":"Inza","year":"2009","journal-title":"Transplant Proc"},{"key":"10.1016\/j.transproceed.2012.06.072_bib19","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.transproceed.2006.12.026","article-title":"Conversion from a calcineurin inhibitor-based immunossupressive regimen to everolimus in renal transplant recipients: effect on renal function and proteinuria","volume":"39","author":"Morales","year":"2007","journal-title":"Transplant Proc"},{"key":"10.1016\/j.transproceed.2012.06.072_bib20","doi-asserted-by":"crossref","first-page":"2859","DOI":"10.1016\/j.transproceed.2010.07.062","article-title":"Late conversion to mammalian target of rapamycin inhibitor\/proliferation signal inhibitors in kidney transplant patients: clinical experience in the last 5 years","volume":"42","author":"Sola","year":"2010","journal-title":"Transplant Proc"},{"key":"10.1016\/j.transproceed.2012.06.072_bib21","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1097\/01.TP.0000074722.79186.A9","article-title":"Apoptosis and treatment of chronic allograft nephropathy with everolimus","volume":"76","author":"Lutz","year":"2003","journal-title":"Transplantation"},{"key":"10.1016\/j.transproceed.2012.06.072_bib22","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.transproceed.2008.03.012","article-title":"Conversion therapy to everolimus in renal transplant recipientes: results after one year","volume":"40","author":"Giron","year":"2008","journal-title":"Transplant Proc"},{"key":"10.1016\/j.transproceed.2012.06.072_bib23","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1093\/ndt\/gfh957","article-title":"Long-term results in renal transplant patients with allograft dysfunction after switching from calcineurin inhibitors to sirolimus","volume":"20","author":"Bumbea","year":"2005","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.transproceed.2012.06.072_bib24","doi-asserted-by":"crossref","first-page":"326","DOI":"10.2215\/CJN.03751106","article-title":"High sirolimus levels may induce focal segmental glomerulosclerosis de novo","volume":"2","author":"Letavernier","year":"2007","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.transproceed.2012.06.072_bib25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.trre.2005.10.005","article-title":"Everolimus (Certican\u00ae) in renal transplantation: a review of clinical trial data, current usage and future directions","volume":"20","author":"Pascual","year":"2006","journal-title":"Transplant Rev"},{"key":"10.1016\/j.transproceed.2012.06.072_bib26","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1111\/j.1600-6143.2008.02272.x","article-title":"Mammalian target of rapamycin inhibitor dyslipidemia in kidney transplant recipients","volume":"8","author":"Kasiske","year":"2008","journal-title":"Am J Transplant"},{"key":"10.1016\/j.transproceed.2012.06.072_bib27","doi-asserted-by":"crossref","first-page":"2424","DOI":"10.1016\/j.transproceed.2006.08.190","article-title":"Conversion to everolimus in kidney transplant recipientes: a safe and simple procedure","volume":"38","author":"Ruiz","year":"2006","journal-title":"Transplant Proc"},{"key":"10.1016\/j.transproceed.2012.06.072_bib28","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.healun.2008.10.003","article-title":"Everolimus-associated pneumonitis in three heart transplant recipients","volume":"28","author":"Otton","year":"2009","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.transproceed.2012.06.072_bib29","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1111\/j.1600-6143.2005.00931.x","article-title":"Calcineurin inhibitor withdrawal from sirolimus-based therapy in kidney transplantation: a systematic review of randomized trials","volume":"5","author":"Mulay","year":"2005","journal-title":"Am J Transplant"},{"key":"10.1016\/j.transproceed.2012.06.072_bib30","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1097\/HJH.0b013e32830ef940","article-title":"Switch of immunosuppression from cyclosporine A to everolimus: impact on pulse wave velocity in stable de-novo renal allograft recipients","volume":"26","author":"Seckinger","year":"2008","journal-title":"J Hypertens"}],"container-title":["Transplantation Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041134512009694?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041134512009694?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,21]],"date-time":"2018-10-21T00:51:25Z","timestamp":1540083085000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0041134512009694"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,12]]},"references-count":30,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["S0041134512009694"],"URL":"https:\/\/doi.org\/10.1016\/j.transproceed.2012.06.072","relation":{},"ISSN":["0041-1345"],"issn-type":[{"value":"0041-1345","type":"print"}],"subject":[],"published":{"date-parts":[[2012,12]]}}}